Direct Probing of Germinal Center Responses Reveals Immunological Features and Bottlenecks for Neutralizing Antibody Responses to HIV Env Trimer

Colin Havenar-Daughton, La Jolla Institute for Allergy and Immunology
Diane G. Carnathan, Scripps Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery
Alba Torrents de la Peña, University of Amsterdam
Matthias Pauthner, Scripps Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery
Bryan Briney, Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery
Samantha M. Reiss, La Jolla Institute for Allergy and Immunology
Jennifer S Wood, Emory University
Kirti Kaushik, La Jolla Institute for Allergy and Immunology
Marit J. van Gils, University of Amsterdam
Sandy Rosales, La Jolla Institute for Allergy and Immunology

Only first 10 authors above; see publication for full author list.

Journal Title: Cell Reports
Volume: Volume 17, Number 9
Publisher: (publisher) | 2016-11-22, Pages 2195-2209
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1016/j.celrep.2016.10.085
Permanent URL: https://pid.emory.edu/ark:/25593/rtq30

Final published version: http://dx.doi.org/10.1016/j.celrep.2016.10.085

Copyright information:
© 2016 The Author(s).
This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Accessed June 10, 2018 9:11 AM EDT
Direct Probing of Germinal Center Responses Reveals Immunological Features and Bottlenecks for Neutralizing Antibody Responses to HIV Env Trimer

Graphical Abstract

Highlights
- Fine needle aspirates quantitatively monitor germinal center activity in lymph nodes
- Neutralizing antibodies correlate with GC B cell magnitude, not ELISA Ab titers
- Tfh cell quality is associated with vaccine-elicited HIV-neutralizing antibodies
- LN FNA probing of GCs should be an immune correlate in HIV vaccine trials

Authors
Colin Havenar-Daughton, Diane G. Carnathan, Alba Torrents de la Peña, ..., Rogier W. Sanders, Guido Silvestri, Shane Crotty

Correspondence
shane@lji.org

In Brief
This study explores the immunological process by which a protein vaccine elicits HIV-neutralizing antibodies. Using direct probing of lymph nodes, Havenar-Daughton et al. show that neutralizing antibody development correlates with germinal center B cell frequencies and Tfh cells and that those responses can be tracked by LN FNAs over time.

Accession Numbers
GSE89148
Neutralizing Antibody Responses to HIV Env Trimer Reveals Immunological Features and Bottlenecks for Generating tier 2 HIV-neutralizing antibody (nAb) responses by immunization remains a challenging problem, and the immunological barriers to induction of such responses with Env immunogens remain unclear. Here, some rhesus monkeys developed autologous tier 2 nAbs upon HIV Env trimer immunization (SOSIP.v5.2) whereas others did not. This was not because HIV Env trimers were immunologically silent because all monkeys made similar ELISA-binding antibody responses; the key difference was nAb versus non-nAb responses. We explored the immunological barriers to HIV nAb responses by combining a suite of techniques, including longitudinal lymph node fine needle aspirates. Unexpectedly, nAb development best correlated with booster immunization GC B cell magnitude and Tfh characteristics of the Env-specific CD4 T cells. Notably, these factors distinguished between successful and unsuccessful antibody responses because GC B cell frequencies and stoichiometry to GC Tfh cells correlated with nAb development, but did not correlate with total Env Ab binding titers.

INTRODUCTION

The efficacy of the vast majority of human vaccines is associated with antibody (Ab) responses (Plotkin, 2010). We still know critically little about the immunological processes important for the generation of neutralizing antibodies and how to maximize such responses during immunization (Burton and Hangartner, 2016; Corti and Lanzavecchia, 2013; Crotty, 2014). Induction of protective antibodies by vaccination is dependent both on features of the immune system and the immunogen. Although CD4 T cells and B cell responses are essential, the specific characteristics of those responses that are responsible for successful development of vaccine-elicited neutralizing antibodies remain poorly characterized for any vaccine. The immunogen must properly mimic the relevant pathogen structure. Minimal, if any, neutralizing antibody responses to meaningful clinical isolate HIV strains (tier 2 or tier 3) have been detected in human HIV vaccine trials (Mascola and Montefiori, 2010; Slepian and Sanders, 2016). The immunogens in those vaccine trials were HIV Env gp120 monomers, not trimers. Rapid progress has been made in recent years in the engineering of HIV vaccine immunogens. The construction of the BG505 SOSIP.664 trimer now permits presentation of a recombinant, well ordered HIV-1 Env trimer to the immune system (Julien et al., 2013; Lyumkis et al., 2013; Sanders et al., 2013). The structure of SOSIP Env trimer is an accurate reflection of the native membrane-expressed HIV-1 Env trimer (Lee et al., 2016).

Non-human primates are an important animal model for testing candidate HIV vaccines because of their evolutionary relatedness to humans (Hessell and Haigwood, 2015). Although non-human primate (NHP) HIV protein immunization studies have been done for over 20 years, significant tier 2 neutralizing antibody responses in immunized non-human primates have only been reported in two studies published recently (Hessell et al., 2016; Sanders et al., 2015). In a first study of four rhesus macaques (RMs) immunized with BG505 SOSIP.664, some animals developed low levels of autologous tier 2 neutralizing antibodies whereas, in the same study, BG505 gp120-immunized macaques did not (Sanders et al., 2015). High titers of
non-neutralizing antibody responses, such as those targeting the V3 loop tip, were also generated in BG505 SOSIP.664-immunized animals. Competition between Ab responses to “difficult” HIV-neutralizing epitopes and “easy” non-neutralizing Env epitopes may limit the generation of neutralizing antibodies (Hu et al., 2015; Sattentau, 2014).

HIV broadly neutralizing antibodies (bnAbs) are highly somatically mutated, and the mutations are necessary for neutralization breadth (Burton and Mascola, 2015; Haynes et al., 2016; Klein et al., 2013). Mutations occur in germinal center (GC) B cells during affinity maturation, whereby GC B cells undergo repeated rounds of somatic hypermutation of their antigen-binding B cell receptor (BCR) and selection by GC T follicular helper (Tfh) CD4 T cells (Crotty, 2014; Victora and Nussenzweig, 2012).

Germinal centers occur in lymphoid tissues, such as lymph nodes, but not in peripheral blood. Consequently, direct studies of germinal centers have not been possible in HIV bnAb+ individuals. Nevertheless, markers connected to GC activity have been associated with the generation of HIV bnAbs. A subset of circulating memory Tfh cells correlated with the generation of HIV bnAbs (Locci et al., 2013). In addition, plasma concentrations of the chemokine CXCL13 correlated with lymph node GC activity (Havenar-Daughton et al., 2016a) and were elevated in bnAb+ individuals (Cohen et al., 2014; Havenar-Daughton et al., 2016a). The importance of GC responses and Tfh cells for the generation of HIV nAbs is also supported by studies of simian immunodeficiency virus (SIV)-infected macaques (Hong et al., 2014; Petrovas et al., 2012; Yamamoto et al., 2015).

Therefore, the data suggest that generation of neutralizing antibody responses against HIV will likely require an immunization regimen that optimizes the induction of GC Tfh cells and GCs. However, for candidate HIV vaccines, these concepts are only inferences. Indeed, a recent large NHP vaccine study with an HIV gp140 immunogen found no association between somatic hypermutation (SHM) and HIV Ab responses (Francica et al., 2015). Little is known about the immunological factors determining whether or not neutralizing antibody responses develop in response to Env trimer immunization.

RESULTS

Generation of Autologous HIV-Neutralizing Antibodies in NHPs Immunized with BG505 SOSIP.v5.2

HIV bnAbs consistently protect NHPs against simian/human immunodeficiency virus (SHIV) infection in passive transfer experiments when the circulating neutralizing Ab (nAb) titers are ≥ ~1:100 (Gautam et al., 2016; Moldt et al., 2012; Shingai et al., 2014), with detectable protection even at titers of 1:20 (Gautam et al., 2016). Immunization of NHPs with a well formed HIV Env trimer, BG505 SOSIP.664, has not consistently elicited autologous tier 2 nAbs of substantial magnitude (≥ 1:50 titer). We immunized a cohort of RMs with a modified BG505 N332 SOSIP designed to improve the stability of the protein (BG505 SOSIP.v5.2; A.T.P. and R.W.S., unpublished data). In addition, we utilized a modified immunization regimen that included subcutaneous bilateral immunizations, which may engage more B and CD4 T cells (Figure 1A). Two different adjuvants were tested in parallel, with groups of eight (PLGA/R848+MPL, “PLGA”) and four (Iscomatrix) animals. Two weeks after the final immunization, serum was tested for autologous tier 2 nAb responses to BG505 T332N pseudovirus. The majority of immunized animals (9 of 12, 75%) generated detectable nAb responses (Figures 1B and S1; Table S1). No significant difference was observed between the two adjuvants. Therefore, all animals from both adjuvant + BG505 SOSIP groups were pooled together for all subsequent analyses. Seven of 12 animals developed peak titers of ≥ 1:50. Four animals generated BG505 nAb titers > 1:200 (defined here as top neutralizers). These are the best autologous tier 2 nAb responses yet reported for HIV Env protein-immunized NHPs. Based on the results of nAb passive transfer studies, we infer that these nAb titers may be sufficient for protection against an autologous tier 2 virus, but this remains to be tested. The animals in this study were not challenged because the study was designed as an immunogenicity study, and necropsy tissues were required for full characterization of the anti-Env vaccine-elicited responses.

Env-Binding Antibodies

Substantial BG505 SOSIP-binding IgG endpoint titers were detected by ELISA for all BG505 SOSIP.v5.2-immunized animals (Figures 1C and S1B). Thus, the difference between RMs that did or did not develop HIV-neutralizing antibodies in response to BG505 SOSIP.v5.2 protein immunization was not that the immunogen was inherently immunological silent in some animals. Therefore, the immunological process limiting nAb responses to Env trimers was unknown. We then examined this knowledge gap.

Longitudinal analyses revealed that the BG505 SOSIP-binding immunoglobulin G (IgG) responses in plasma after the priming immunization were minimal (Figure 1C). This is a common feature of protein immunizations in large animals and humans (Evans et al., 2001; McElrath et al., 2000; West, 1989) and has been previously observed for BG505 SOSIP (Sanders et al., 2015). BG505 SOSIP-binding IgG in plasma increased substantially after the second immunization and after the third and fourth immunizations (Figure 1C). Peak titers did not differ statistically between the two adjuvant groups (Figure S1B).

BG505 nAb titers did not correlate with BG505 SOSIP-binding IgG after BG505.v5.2 immunization (Figure 1D). Additionally, tier 2 nAbs were not detected to heterologous clade A strains (Experimental Procedures). The observation that BG505 SOSIP-binding IgG titers were not predictive of autologous BG505 nAb titers indicated that the BG505 SOSIP-binding IgG was composed of antibody responses to a mixture of neutralizing and non-neutralizing epitopes in ratios that are variable from one animal to another. Non-neutralizing Abs can bind the exposed base of the trimer, the V3 loop tip, CD4i sites, or gp120 breakdown products. Anti-V3 antibody responses can be an immunodominant yet irrelevant response to Env immunization or HIV infection (Mascola et al., 1996; Mascola and Montefiori, 2010; McGuire et al., 2014). One aspect of BG505 SOSIP.v5.2 protein design was the modification of the BG505 SOSIP.664 V3 region to reduce exposure of the V3 loop in vitro (de Taeye et al., 2015). A BG505 V3 peptide ELISA was performed to detect V3 loop-specific IgG in BG505 SOSIP.v5.2-immunized RMs. The BG505 SOSIP.v5.2 modifications did not
eliminate the immunization-induced antibody response to the BG505 V3 loop (Figure S1C), suggesting that the V3 loop becomes exposed in vivo during natural protein breakdown processes (Hu et al., 2015). Because the V3 loop is a major target of irrelevant tier 1 nAb responses (Mascola et al., 1996; Mörner et al., 2009; Sanders et al., 2013), tier 1 nAb responses were measured. Autologous BG505 tier 2 nAb titers in BG505 SOSIP.v5.2-immunized RMs did not correlate with tier 1 nAb titers to MN.3 and SF162 pseudoviruses (Figure 1E), indicating that HIV Env trimer immunization-elicited neutralizing antibodies...
against tier 1 and tier 2 viruses are unrelated. The V3 loop Ab response correlated with the tier 1 MN.3 nAb response, consistent with the V3 loop being in an open confirmation on tier 1 HIV strain pseudoviruses (r = 0.64, p = 0.03; Figure S1D). Interestingly, the V3 loop responses plateaued after the second immunization, whereas total BG505 SOSIP IgG continued to increase, resulting in a higher ratio of SOSIP ELISA- to V3 loop ELISA-specific Abs after the fourth versus the third immunization (Figure 1F). In summary, serology showed that a range of autologous nAb responses were generated by BG505 SOSIP.v5.2 immunization, including animals with high autologous tier 2 nAb titers and animals with undetectable autologous nAb, without correlation to the overall magnitude of the anti-Env IgG response. Therefore, what was the immunological basis for the qualitatively different response by nAb responders and non-responders? We considered that understanding GC and Tfh cell responses within the draining lymph nodes (LNs) may be critical to assess the immunological processes responsible for generating immunization-elicited HIV tier 2-neutralizing antibodies.

**Fine Needle Aspirates Quantitatively Monitor Germinal Center Activity in Draining Lymph Nodes**

GC B cells and GC Tfh cells are not present in blood and, therefore, can only be studied with lymphoid tissue samples. Whole LN excision has been rarely performed in human vaccine studies. Whole LN excisional biopsies can be performed as part of vaccine studies in NHPs; however, removal of a draining LN has numerous drawbacks and can only be done once, thus precluding longitudinal assessment of the vaccine-induced GC responses. This inability to directly quantify GC activity (GC B cells and GC Tfh cells) in response to an immunization has remained a vexing “black box” problem for vaccine immunology of monkeys and humans. Therefore, we used fine needle aspirates (FNAs) of the draining LNs to sample GC B cells and GC Tfh cells.

The LN fine needle aspiration technique is widely used in clinical oncology for non-quantitative diagnostic purposes as a simple, non-disruptive to the antibody and GC responses, and properly quantified GC B and GC Tfh cell populations within an LN.

**Massive Germinal Center Responses to Priming Protein Immunization**

A priming immunization with a protein antigen is generally considered a small immunological event in humans and large animal models (Evans et al., 2001; McElrath et al., 2000; West, 1989), unlike in mice. Antibody titers in the plasma are minimally elevated after an initial immunization (Figure 1C; Sanders et al., 2015). In addition, CD4 T cell responses in the blood after protein immunizations are generally undetectable or barely detectable (McElrath et al., 2000; Verschoor et al., 1999). However, very little is directly known about the magnitude of the CD4 T cell and B cell responses at the primary site of the immune response to a protein immunization in monkeys or humans. Thus, GC responses were examined in RMs immunized once with BG505 SOSIP.v5.2. GC Tfh cells were dramatically increased in the protein + adjuvant immunization groups 21 days after the priming immunization (unimmunized versus adjuvant + BG505 SOSIP.v5.2, p = 0.0001), with mean GC Tfh cell frequencies of 7.3% of total CD4 T cells, respectively (Figures 3A and S3A). The frequencies of GC B cells were vastly increased in the protein + adjuvant immunization groups (unimmunized versus adjuvant + BG505 SOSIP.v5.2, p = 0.0001; Figure 3B). On average, GC B cell frequencies of 20.2% were observed in draining LNs after a single immunization. That is vastly higher than in protein-immunized mice (3% or lower) (Hu et al., 2015; Kuraoka et al., 2016). The frequency of GC B and GC Tfh cells in immunized RMs strongly correlated in the primary immune response (r = 0.86, p < 0.0001; Figure 3C), consistent with the
Figure 2. FNAs Monitor GC Activity in Draining Lymph Nodes

(A) Cell recovery from LN FNAs (n = 24). Error bars show 95% confidence intervals.

(B) Flow cytometry from LN FNA samples gated on GC B cells among CD20+ B cells (left) or GC Tfh cells among CD4+ T cells (right).

(C) Experimental group design. Bx, whole LN biopsy.

(D) GC B cell frequency in whole LN biopsies 3 weeks after the fourth immunization (n = 12/group). LNs were either previously sampled by FNA (group 1) or not (group 2).

(E) GC Tfh cell frequency in whole LN biopsies 3 weeks after the fourth immunization (n = 12/group). LNs were either previously sampled by FNA (group 1) or not (group 2).

(F) BG505 SOSIP.v5.2 ELISA titers at week 0 and week 14 for animals that had undergone previous LN FNAs (group 1) or not (group 2).

(G) Percentage of cells sampled per LN by FNA (n = 24).

(H) GC B cell frequency determined from FNA or whole LN biopsy (n = 24). Each point represents an individual LN sampled by fine needle aspiration and then by whole LN biopsy.

(I) GC Tfh cell frequency as in (H).

See also Figure S2.
interdependence of GC B cells and GC Tfh cells (Crotty, 2011; Johnston et al., 2009; Victora et al., 2010). The “adjuvant only” control group did not differ from the unimmunized group (Figures 3A and 3B), confirming that the GC responses to the SOSIP immunization were antigen-specific. In summary, strikingly high frequencies of GC B and GC Tfh cells are induced in draining LNs of monkeys after a single protein + adjuvant immunization, discordant from the primary serological response to the immunogen.

Longitudinal Monitoring of Germinal Center Responses in Individual LNs during an Immunization Series

Multiple immunizations will likely be required to successfully generate HIV bnAbs via a vaccine (Burton and Hangartner, 2016; Haynes et al., 2016; Klein et al., 2013). Therefore, booster immunizations need to generate germinal centers. In mice, booster immunizations of protein + adjuvant predominantly induce strong plasmablast responses but can induce some 2′ GC responses (Dogan et al., 2009; Pape et al., 2011). The extent to which secondary GCs occur after immunizations in monkeys or humans and how the 2′ GC response compares with the 1′ GC response in the same individual is unknown.

Six weeks after the priming immunization, the first booster immunization was given (Figure 1A). As a group, draining LNs from immunized RMs had statistically higher GC B cell frequencies than unimmunized RMs (p = 0.03; Figure 4A), whereas there was a trend for increased GC Tfh cells (p = 0.1; Figure 4B). Because LN FNA samples were obtained from the same draining LN sites after each immunization, GC recall responses could be directly compared with the priming responses. Mean GC B cell frequencies after the second immunization were only 60% of the GC B cell frequencies observed after the first immunization (13.7% versus 22.4%; paired p = 0.006; Figure 4C). Similarly, mean GC Tfh cell frequencies were only 43% of the GC Tfh cell frequencies observed after the first immunization (3.4% versus 8.0%, paired p = 0.004; Figure 4D). Thus, the second immunization generated markedly fewer GC Tfh and GC B cells than the primary immunization.

After the second immunization, anti-Env plasma antibody titers increased by a factor of 17 on average (Figure 1C). The frequency of GC B cells and GC Tfh cells after the first immunization exhibited strong trends for a correlation with the BG505 SOSIP binding titers 2 weeks after the second immunization (GC B cells: r = 0.62, p = 0.06; GC Tfh cells: r = 0.62, p = 0.06; Figures 4E and 4F). In addition, Env-specific plasmablasts were present in the blood 5 days after the second immunization but not in unimmunized animals (p = 0.001; Figure 4G). Taken together, robust GC activity induced by the priming immunization led to strong plasmablast and Env antibody responses upon the next immunization.

Diverse patterns of GC activity were observed in individual animals (Figures 4H and S3D), but overall GC responses after all booster immunizations tended to be lower than the primary response. The frequency of GC B and GC Tfh cells after the third and fourth immunizations were significantly higher than in the unimmunized control group at both time points (Figures 4I and 4J).

To investigate why GC responses generated by booster immunization may be lower in magnitude than those generated by the primary immunization, GC responses were examined 6 weeks after the final immunization. This was chosen to match the interval between previous immunizations. Substantially elevated frequencies of GC B cells and GC Tfh cells were still present in the draining LNs 6 weeks after the final immunization (GC B cells, unimmunized versus immunized, 3.5% versus 10.5%, p < 0.0001;
Figure 4. Longitudinal Monitoring of GC Responses

(A) Frequency of GC B cells in draining LNs 3 weeks after the second immunization (week 9) compared with matched LNs from unimmunized RMs (none).
(B) Frequency of GC Tfh cells as in (A).
(C) Frequency of GC B cells as in (A), with Wilcoxon matched pairs rank test.
(D) Frequency of GC Tfh cells as in (B), with Wilcoxon matched pairs rank test.
(E) GC B cell frequency (draining LNs at week 3, average of left and right inguinal LNs) compared with BG505 binding titers.
(F) GC Tfh cell frequency as in (E).

(legend continued on next page)
Additional LN FNAs revealed GCs persisting for up to 120 days after immunization (Figure 4K). Therefore, given the magnitude of the GC responses observed ~42 days after the final immunization, and the magnitude of the GC responses observed 21 days after each immunization, it is highly likely that the booster immunizations at 42-day intervals were given in the face of substantial ongoing GC responses initiated by the previous immunization. That may have negative consequences.

**Env-Specific Tfh Cells in LNs**
The intrinsic biology of GC Tfh cells dictates that these cells be stingy cytokine producers (Dan et al., 2016; Havenar-Daughton et al., 2016b). This explains why it has been very difficult or impossible to detect antigen-specific GC Tfh cells by intracellular cytokine staining in most contexts (Hessell et al., 2016; Havenar-Daughton et al., 2016b), resulting in the impression that antigen-specific GC Tfh cells are quite rare. We have developed a cytokine-independent methodology, referred to as the activation-induced marker (AIM) method (Dan et al., 2016; Havenar-Daughton et al., 2016b), for detecting antigen-specific GC Tfh cells. AIM shows an acceptable background in adjuvant only-immunized macaques and retains fidelity of the GC Tfh cell phenotype after stimulation. Strikingly, a median of 6.4% of GC Tfh cells were Env-specific 21 days after the final Env trimer immunization (range, 1.3%–39.3%; Figures 5A and 5B). Env-specific non-Tfh cell responses were also present (Figures 5C and 5D). Together, these data demonstrate surprisingly robust antigen-specific GC Tfh and non-Tfh CD4 T cell responses to a protein immunization.

**GC B Cells and Autologous nAbs**
Directly probing the GCs at the primary site of the immune response allowed for interrogation of specific immunological factors potentially predictive of the generation of HIV nAbs. The strongest immunological feature associated with the development of BG505 nAbs was the frequency of GC B cells after booster immunizations (Figures 6A and 6B). A correlation between nAbs and the average frequency of GC B cells in response to the third and fourth immunizations was observed for the eight serial LN FNA animals that was of borderline statistical significance (r = 0.71, p = 0.06; Figure 6A). A wider analysis, including all animals for which LN samples were available, demonstrated a strong association between GC B cell activity after the final (fourth) immunization and the development of nAbs (p = 0.007; Figure 6B). The median frequency of LN GC B cells in top neutralizers was almost 3-fold higher than in non/low neutralizers (median GC B cells; top, 20.3% versus non/low, 7.6%; Figure 6B). Tier 2 nAb development was also associated with GC B cell frequencies after the second and third immunizations (Figure 6B). In contrast, neither BG505 SOSIP IgG ELISA binding titers (p = 0.88; Figure S4A) nor tier 1 nAbs (p = 0.58; Figure S4B) correlated with GC B cell activity to the later immunizations, highlighting the specificity of the association between the ability of the immune system of select animals to re-elicit strong GC responses to booster immunizations and the development of a strong autologous tier 2 nAb response. In conclusion, GC B cell frequencies in draining LNs after the booster immunizations were strongly associated with successful development of autologous tier 2 neutralizing antibodies.

Given the large magnitude of the GC responses in the LNs of top neutralizers, we reasoned that GC B cell clonal lineages responding to HIV Env may be individually identifiable by next generation sequencing (NGS) as clusters of closely related BCR sequences. We sequenced IgM and IgG BCRs from LN FNA samples using NGS (Figures 6C, 6D and S5). Large to very large lineages of 50–30,000 independent sequences from the LNs of Env-immunized animals were readily organizable into phylogenetic trees. We focused the analysis on the top 50 largest lineages per immunized animal (Figures S5B and 6C). Phylogenetic trees were densely populated with closely related sequences (Figure 6D), many differing by only a single nucleotide, consistent with expectations for large active GCs, and also likely including some plasma cell and memory B cell sequences. Mutation frequencies per lineage increased over time during the course of the immunization (p < 0.04; Figures 6D and S6E). Three of the top 50 largest lineages from one of the top neutralizers, ROP15, were confirmed to be BG505 trimer-specific by cross-referencing the NGS lineages against an initial set of 109 BCR sequences of BG505 SOSIP.v5.2 trimer-binding B cells isolated from the peripheral blood or spleen at necropsy (Figures 6D, S5C, and S5F). Based on the large magnitude of the GC responses in the draining LNs of immunized animals above that of unimmunized animals (Figure 6B) and animals receiving adjuvant alone, the majority of B cell lineages observed in the LN FNA NGS are likely Env-specific, but that awaits future studies with additional sorts of blood Env-binding B cells.

Analysis of the phylogeny of the largest BG505 SOSIP-specific lineage (884 independent sequences, see Experimental Procedures) from ROP15 revealed a number of interesting characteristics. The lineage emerged early in the immune response (detectable after the first immunization), and BCR sequences close to the unmutated common ancestor (UCA) were identified (Figures 6D, S5C, and S5F). The lineage contained interspersed IgM- and IgG-switched B cells (data not shown). The lineage was detected after each of the four immunizations. The lineage had evidence of extensive hypermutation and affinity maturation over time. Additionally, the lineage was found in both left and right draining LNs.
right draining lymph nodes (Figures 6D, S5C, and S5F). Expanding the analysis to the top 50 largest lineages per animal, these patterns were consistent. LN FNA BCR NGS revealed unmutated common ancestor clones for the majority of the lineages (Figure S5G). Furthermore, the majority (60%–80%) of lineages were observed in multiple LN FNA samples (Figure 6C). A substantial fraction of the lineages were found in both the left and right draining LNs (26%–66%; Figure 6C). In sum, LN FNA BCR NGS analysis identified large clonal lineages that could be traced longitudinally over the course of the immunization regimen. For BG505 SOSIP-specific sequences from a top neutralizer, the lineages were detected at the earliest time point, were detectable at all subsequent time points, were detectable in both left and right lymph nodes, and exhibited increased mutations over time.

**Tfh Cell Quality Is Associated with Autologous nAbs**

Tfh cells are not only required for GC reactions to occur but are also limiting (Johnston et al., 2009; Victora et al., 2010). After the fourth immunization, which had the strongest association between GC B cells and nAbs (Figure 6B), the correlation between GC B cell and GC Tfh frequencies was modest ($r = 0.53$, $p = 0.05$; Figure S3A) when compared with the tight relationship between GC B cells and GC Tfh cell frequencies after the first immunization ($r = 0.86$, $p < 0.0001$; Figure 3C). This led us to consider whether the quality of the Tfh cells differed. One way in which Tfh quality can be conceptualized is the number of GC B cells supported per GC Tfh cell. The GC B:GC Tfh cell stoichiometry was more than doubled in top neutralizer RMs compared with non/low neutralizer RMs (GC B cell to GC Tfh ratio: top, 6.8 versus non/low, 3.1, $p = 0.005$; Figures 7A, 7B, and S6A; GC B cell to GC Tfh ratio: top versus low, $p = 0.049$; top versus non, $p = 0.029$; Figure S6B). The increased GC B:GC Tfh cell ratio suggested that top neutralizers had larger germinal center responses because their Tfh cells were capable of supporting larger GC B cell populations.

LN FNA GC Tfh cell numbers were too limiting for additional analysis. Therefore, we examined whether Env-specific CD4 T cells were detectable in peripheral blood. Substantial frequencies of Env-specific CD4 T cells were detected in the blood both 1 and 3 weeks after the first immunization (control versus week 1, $p = 0.0017$; control versus week 3, $p = 0.0017$; Figures 7C and 7D). Env-specific CD4 T cell responses were also robust in the blood after the final immunization, at week 19 (control versus week 19, median: 0.16% versus 0.92%, $p = 0.0018$; Figures 7C and 7D). Elevated frequencies of Env-specific CXCR5+ CD4 T cells were also detected in the blood at the same time points ($p < 0.003$; Figures S6C and S6D). To further assess the quality of the CD4 T cell responses,
Figure 6. GC B Cell Relationships to Autologous nAbs and Longitudinal Sequencing Analysis of Clonal Lineages and Affinity Maturation Identified in LN FNAs of BG505 SOSIP.v5.2-Immunized RMs

(A) GC B cells after the third and fourth immunizations compared with the BG505 neutralization titer. Each point represents the average of four GC B cell measurements (two draining LNs at two time points) for an individual animal. Longitudinal GC B cell data were only acquired from the eight RMs undergoing FNA analysis. Neutralizing titers are log-transformed values.

(B) GC B cell frequencies in draining LNs after each immunization for top neutralizers (red) and non/low neutralizers (black). Points represent individual LNs. The dotted line indicates the mean frequency of GC B cells in unimmunized RM LNs.

(legend continued on next page)
200–5,000 AIM+ Env-specific CD4 T cells were sorted from peripheral blood mononuclear cells (PBMCs) after the fourth immunization and analyzed by RNA sequencing (RNA-seq) (Figures S6E and S6F; Table S2). Extensive gene expression differences were observed between Env-specific CD4 T cells in high neutralizers and non-neutralizers (1,012 upregulated, 1,354 downregulated > 2-fold; Figure 7E). Strikingly, Tfh-associated genes were more highly expressed in top versus non-neutralizers (Figure 7E). These included the two most critical proteins for Tfh help to B cells, IL-21 and CD40L. IL-21 was one of the most differentially expressed genes between top neutralizers and non-neutralizers (8-fold increase; Figure S6G), with a wide range of expression among low neutralizers. In addition, two prominent proteins in human Tfh cell development, ICOS and IL-12Rb1 (Crotty, 2014; Ma et al., 2009, 2012; Schmitt et al., 2013) were also more highly expressed in top neutralizers than in non-neutralizers (Figure S6G). Significantly higher CD40LG, ICOS, and IL12RB1 gene expression was observed when top neutralizers were compared with the group of non/low-neutralizers (CD40LG, p = 0.036; ICOS, p = 0.017; IL12RB1, p = 0.018; Figure 7F). Thus, generation of autologous tier 2 nAbs was associated with Tfh cell quality, as measured by GC B cell to GC Tfh stoichiometry and Env-specific CD4 T cell gene expression data. Together, the correlations between autologous tier 2 nAbs, GC B cell frequency, and Tfh cell quality identity GC responses as a central limiting process for immunization-induced generation of autologous tier 2 nAbs.

**DISCUSSION**

Here, we demonstrate the generation of significant titers of autologous HIV tier 2 nAbs in the majority of BG505 SOSIP.v5.2-immunized RMs. Although the BG505 nAbs results are the best reported to date, the observation of nAb responders and non-responders highlights the difficulties facing HIV vaccine development. The T and B cell responses of these animals were intensively interrogated using a suite of innovative techniques, including longitudinal LN FNAs to quantify GC Tfh cells and GC B cells, longitudinal GC BCR sequencing, antigen-specific GC Tfh quantitation by AIM, antigen-specific peripheral blood Tfh quantitation by AIM, and RNA-seq of Env-specific CD4 T cells. GC B cell frequencies in the draining LNs in response to the final immunization was the most predictive factor for the development of autologous nAbs, with the top neutralizers having 3-fold more responding GC B cells than animals that only made non-neutralizing Ab responses. Furthermore, the results indicate that Tfh cell quality is a key factor for the development of autologous nAbs. Thus, GCs are limiting for nAb development in response to immunization with a candidate HIV vaccine immunogen. These results suggest that direct probing of GCs should be considered as a central immune correlate in HIV vaccine trials.

HIV-neutralizing epitopes of circulating tier 2 HIV viruses are difficult epitopes for the B cell response to recognize (Burton and Hangartner, 2016; Hu et al., 2015; McGuire et al., 2014; Sanders et al., 2015). For example, immunization with gp120, which contains the high-mannose patch, does not elicit N332 supersite-specific bnAbs. In HIV infection, autologous nAbs generally take many months to develop. nAb responses to SOSIP immunization require three or more immunizations to develop (de Taeye et al., 2015; Sanders et al., 2015), if at all (Hu et al., 2015). In contrast, non-neutralizing Ab epitopes, such as the V3 loop, are easy epitopes for B cells to recognize and are robustly elicited by any HIV Env construct. In the case of HIV-1 Env, difficult neutralizing epitopes and easy non-neutralizing epitopes are on the same immunogen molecule, and, therefore, B cells recognizing each type of epitope will compete for the same protein available. Based on the data here and in the literature, we posit that non-neutralizing B cell responses such as V3 specificities dominate the early response. This presents a daunting challenge for Env-specific B cells with neutralization potential (i.e., targeting Env epitopes for which neutralization is possible if the antibody has sufficient affinity) because they are at a significant competitive disadvantage compared with the Env-specific B cells targeting non-neutralizing epitopes. Thus, in this scenario, the factor that distinguishes animals that develop nAbs from animals that fail to develop nAbs may be the capacity of their immune system to elicit and maintain Env-specific B cells targeting neutralizing epitopes early on in the immune response even though B cells targeting neutralizing epitopes are less competitive than high-affinity (or high-frequency) B cells specific to easy non-neutralizing epitopes.

How can B cells with neutralizing specificities but initial low affinity for the immunogen best be elicited and maintained in the GC response? Three possibilities are increasing Tfh help, increasing the number of B cells exposed to the immunogen, and favoring presentation of neutralizing epitopes over non-neutralizing epitopes on the immunogen. CD4 T cell help can be a limiting factor for successful progression of a low-affinity B cell into GCs in the face of competition from high-affinity B cells in the context of nitrophenol hapten immunization in mice (Schwickert et al., 2011). Thus, by extension, early availability of Tfh cells may be required for successful recruitment...
of low-affinity HIV Env-specific B cells with nAb potential. The data presented here indicate a role for Tfh cells in the development of vaccine-elicited HIV nAbs. Therefore, methods of inducing additional Tfh cells could be useful (Locci et al., 2016), or enhancing the quality of the Tfh cells. Second, if B cells with neutralizing specificities are rare, then engaging larger numbers of B cells could increase the likelihood of stimulating an nAb B cell lineage. Diverse GC responses were observed in
the right and left draining LNs of the same animal after bilateral immunizations, implying a stochastic element to the response and highlighting the potential value of immunizing at two sites to increase the number of responding B and T cells. A third mechanism by which B cells with neutralizing specificities could be favored may be minimizing the presentation of non-neutralizing epitopes. To this end, designs to stabilize Env trimers (de Taeye et al., 2015; Guenaga et al., 2015) or protect the immunogen via slow release mechanisms (Hu et al., 2015; Tam et al., 2016) are of interest. One potential metric for assessing the relative neutralizing and non-neutralizing Ab responses is the BG505-specific:V3-specific IgG ratio. However, this ratio did not correlate with neutralization, likely because of the presence of other non-neutralizing epitopes present on the trimer (Hu et al., 2015). A shift in the ratio of BG505-specific:V3-specific IgG when immunizing with BG505.v5.2 was observed, suggesting that BG505 SOSIP.v5.2 partially limits V3 loop immunogenicity, which may shift the immunodominance profile of the B cell response.

GC B cell sequencing data indicate that memory B cells actively re-circulated after each immunization and reseeded new GCs. The phylogeny structures suggest that the seeding of new GCs by memory B cells was likely to come not from the most mutated branches of the lineage but, instead, from moderately mutated subclones. This is consistent with cross-sectional data from mouse immunizations with model antigens (Kaji et al., 2012), suggesting a certain stochasticism to both the GC response (Tas et al., 2016) and the recall of memory B cell clones for reseeding new GCs and perhaps a bias toward recall of less mutated memory B cells. Intriguingly, for a top neutralizer animal, the largest lineages contained more BCR sequences from later time points, consistent with initially subdominant responses (i.e., lineages with neutralizing potential) becoming more dominant in top neutralizer animals over time.

LN FNAs provided a powerful technique for the identification and quantitation of GC B and GC Tfh cells and for longitudinal GC analysis in each animal. FNA LNcs in humans were previously shown to be non-disruptive to the LN architecture (Prasad et al., 1996). We expanded on the recent experimental use of LN FNAs in NHPs that identified GC Tfh cells at steady state (Xu et al., 2015) and LN FNA analysis in humans where total CD4 T cells responses were measured after immunization (Tatovic et al., 2015). We demonstrated that GC B cells are identifiable in LN FNAs, that GC Tfh cells and GC B cells are quantitatively represented in LN FNAs, that vaccine-specific GC Tfh cells could be quantitated in LN FNAs, and that clonal expansion and sequence evolution of antigen-specific B cell responses can be tracked longitudinally in fine detail in LN FNAs.

Unexpectedly, robust GC B and GC Tfh cell populations were induced in the draining LNs of NHPs after a single protein + adjuvant immunization even while minimal circulating Ab was generated. Also unexpectedly, the second immunization yielded significantly lower frequencies of GC cells than the first immunization. Given the magnitude and longevity of the GC responses observed, the short interval between immunizations appeared to have contributed to impairing the GC response to the booster immunization. Why poor GC boosting occurred at the shorter interval is unknown. One possibility is that new GC reactions may quench existing germinal centers (McHeyzer-Williams et al., 2015), prematurely terminating SHM and causing some cost to the initiation of new germinal centers.

Somatic hypermutation increased in the major GC B cell lineages upon each successive immunization in this study. A recent gp140 HIV Env immunization study did not find an association between somatic hypermutation and different adjuvant groups (Francica et al., 2015). However, no tier 2 nAbs were elicited in any animals in that study, only non-neutralizing antibodies. Thus, we speculate that only "easy" non-neutralizing/tier 1A B cell responses were elicited by that immunogen, which rapidly plateaued in affinity. In contrast, here, development of autologous tier 2 nAbs was observed in the majority of the animals immunized with BG505.v5.2, and major GC B cell lineages did evolve extensively during the course of the immunizations.

Understanding the GC response by directly accessing and interrogating GC cells may be particularly important in upcoming human phase I clinical trials that will test immunogens that are not expected in and of themselves to immediately generate HIV bnAbs but are designed to be important initial steps on a path to bnAb development (Jardine et al., 2016). Our findings indicate that GC Tfh cell and GC B cell magnitude and quality are likely to be central for the success of those approaches and should be examined directly or by surrogate indicators. The findings and approaches reported here are also likely to be valuable for vaccine development to other high-priority pathogens.

EXPERIMENTAL PROCEDURES

A detailed description of the experimental methods, procedures, flow cytometry panels (Table S3), and associated references is available in the Supplemental Experimental Procedures.

Statistics

The Mann-Whitney test was used for evaluating differences among groups. The Wilcoxon test was used to evaluate differences between samples obtained at different time points from the same animal otherwise noted. The Spearman correlation test was used for correlative analysis unless otherwise noted. Prism 6.0 (GraphPad) was used for all statistical analyses.

ACCESSION NUMBERS

The accession number for the RNA-seq data reported in this paper is GEO: GSE89148. The accession number for the BCR sequencing data reported in this paper is SRA: PRJNA351269.

SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures, six figures, and three tables and can be found with this article online at http://dx.doi.org/10.1016/j.celrep.2016.10.085.

AUTHOR CONTRIBUTIONS


Cell Reports 17, 2195–2209, November 22, 2016 2207
ACKNOWLEDGMENTS

We thank Francois Villinger for assistance with FNA pilot studies (University of Louisiana at Lafayette). We thank the Flow Cytometry Core at the La Jolla Institute for Allergy and Immunology for expert cell sorting assistance. We thank Vijay Pandurangan (LJBl Bioinformatics), Jason Greenbaum, and Alex Fu of LJBl Bioinformatics for assistance with the RNA-seq analysis. This work was supported by the Scripps CHAVI-ID (NIH Grant U16-AI100663 to S.C., G. Silvestri, D.B., B.P., and R.A.) and National Primate Research Center funding PS1 RR000165/OH111132, to the Yerkes National Primate Research Center, with additional grants from NIAID (Emory Center for AIDS Research, NIH Grant P30-AT5-504, to G. Silvestri, and HIVRAD, NIH Grant P01 AI110657 to R.W.S. and JPM), the Gates Foundation (CAVD, to B.P. and S.C.), and the European Research Council (ERC-StG-2011–280829-SHEV, to R.W.S.).

Received: August 5, 2016
Revised: September 16, 2016
Accepted: October 25, 2016
Published: November 22, 2016

REFERENCES


